View by Specialty

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

Genitourinary Cancer News

SPONSORED CONTENT
Save
SPONSORED CONTENT
February 15, 2021
6 min read
Save

Enfortumab vedotin confers benefit ‘across the spectrum’ of advanced urothelial carcinoma

Enfortumab vedotin confers benefit ‘across the spectrum’ of advanced urothelial carcinoma

Results of two studies presented at Genitourinary Cancers Symposium showed treatment with enfortumab vedotin-ejfv benefited patients with locally advanced or metastatic urothelial carcinoma previously treated with a PD-1 or PD-L1 inhibitor.

SPONSORED CONTENT
February 02, 2021
3 min read
Save

ASCO names molecular profiling of gastrointestinal cancer ‘Advance of the Year’

ASCO names molecular profiling of gastrointestinal cancer ‘Advance of the Year’

ASCO has named molecular profiling driving progress in gastrointestinal cancer as its Advance of the Year, acknowledging improvements in treatment that have resulted from molecular testing of patients’ tumors.

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

SPONSORED CONTENT
January 27, 2021
1 min read
Save

Medical oncologist appointed chair of bladder cancer advisory board

Medical oncologist appointed chair of bladder cancer advisory board

Elizabeth Plimack, MD, MS, has been appointed chair of Bladder Cancer Advocacy Network’s scientific advisory board.

SPONSORED CONTENT
January 22, 2021
1 min read
Save

FDA approves first-line Opdivo-Cabometyx regimen for advanced renal cell carcinoma

FDA approves first-line Opdivo-Cabometyx regimen for advanced renal cell carcinoma

The FDA approved nivolumab in combination with cabozantinib as first-line treatment of patients with advanced renal cell carcinoma, according to a manufacturer-issued press release.

SPONSORED CONTENT
January 19, 2021
1 min read
Save

FDA grants fast track designation to padeliporfin ImPACT for urothelial cancer subset

FDA grants fast track designation to padeliporfin ImPACT for urothelial cancer subset

The FDA granted fast track designation to padeliporfin immune photo activated cancer treatment as treatment for adults with low-grade upper tract urothelial carcinoma.

SPONSORED CONTENT
January 12, 2021
3 min read
Save

US cancer mortality continues to decline at record pace

US cancer mortality continues to decline at record pace

Overall cancer mortality in the U.S. decreased by 31% between 1991 and 2018 amid continued advances in lung cancer treatment, according to American Cancer Society’s 70th annual report on cancer statistics.

SPONSORED CONTENT
December 10, 2020
13 min read
Save

Obesity-associated cancers: An emergent problem among younger adults

Obesity-associated cancers: An emergent problem among younger adults

The increasing prevalence and troubling consequences of obesity in the United States have been well-documented.

SPONSORED CONTENT
November 23, 2020
2 min read
Save

Noninvasive assay outperforms standard cytology in detection of urothelial carcinoma

Noninvasive assay outperforms standard cytology in detection of urothelial carcinoma

A urine-based whole-genome sequencing assay demonstrated high specificity and comparable sensitivity to standard cytology for the detection of urothelial carcinoma, according to study results published in Clinical Cancer Research.

SPONSORED CONTENT
November 11, 2020
2 min read
Save

Diagnostic radiation below the waist may increase risk for testicular cancer

Diagnostic radiation below the waist may increase risk for testicular cancer

Exposure to diagnostic radiation below the waist may increase risk for testicular germ cell tumors, according to results of a case-control study published in PLOS One.

SPONSORED CONTENT
November 10, 2020
8 min read
Save

Training essential to understand cancer risks, address barriers facing LGBTQ individuals

Training essential to understand cancer risks, address barriers facing LGBTQ individuals

Lesbian, gay, bisexual, transgender or queer individuals, or sexual and gender minorities, have been shown to have a disproportionate risk for cancer.

View more